No Data
TD Cowen Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $32
TD Cowen Sticks to Its Hold Rating for Pfizer (PFE)
Stuart Therapeutics Announces the Appointment of Two New Board Members
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Why Pfizer Inc. (PFE) Is One of the Best Stocks to Buy and Hold for 3 Years?
Pfizer Just Reassured Investors, but Is the Stock a Buy?